Tetrathiomolybdate in Hormone Refractory Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

Purpose: The aim of this clinical trail is to evaluate Tetrathiomolybdate (TM) in the treatment of hormone refractory prostate cancer.

Key facts

Study ID

NCT00150995

Run by

University of Michigan Rogel Cancer Center

People needed

19

Starts

2001-05-01

Expected to finish

2006-04-01

Last updated by the study team

2015-01-21

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• The University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.